retatrutide developer eli lilly wants to replace Zepbound with an even stronger weight loss drug Lilly's Retatrutide: Toward the End

The N-arachidonoylphenolamine dose-dependently inhibits NMDA-induced excitotoxicity in organotypic hippocampal slice cultures and the expression of interleukin-6 (IL-6), tumor necrosis factor (TNF-), and microsomal prostaglandin E synthase-1 and attenuates neuronal damage [47]

A South Korean research team has now identified the cause and proposed a strategy that involves managing overall metabolic status, not just body weight

We take a comprehensive and personalised approach to weight loss that focuses on sustainable lifestyle changes and individualised recommendations for optimal success

Learn more about the AACE-recommended testing for metabolic dysfunction-associated steatotic liver disease (MASLD) using the fibrosis-4 (FIB-4) index and enhanced liver fibrosis (ELF) score